Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound for treating and/or preventing neurodegenerative related disease

A neurodegenerative and chemical compound technology, applied in nervous system diseases, sensory diseases, organic chemistry, etc., can solve problems such as single target, few types, and poor long-term efficacy

Inactive Publication Date: 2012-11-21
SICHUAN UNIV
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the drugs currently used to treat this disease have problems such as fewer types, single target, more toxic and side effects, and poor long-term efficacy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for treating and/or preventing neurodegenerative related disease
  • Compound for treating and/or preventing neurodegenerative related disease
  • Compound for treating and/or preventing neurodegenerative related disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 The protective effect of drugs on nerve cells

[0027] MTT method is used to screen the protective effect of the compounds disclosed in the present invention on hydrogen peroxide-induced injury of PC12 nerve cells. PC12 neuronal cells were purchased from the Cell Bank of the Type Culture Collection Committee of the Chinese Academy of Sciences, and used DMEM medium containing 10% FBS at 37°C in 5% CO 2 Routine culture in a saturated humidity incubator. Take cells in good logarithmic growth phase, digest with 0.25% trypsin, make cell suspension, count 5×10 4 cells / mL, the cell inoculation volume was 100 μL / well, and cultured in an incubator. After 24 hours, different concentrations of the compound solutions disclosed in the present invention (final concentration 1, 10 μM) were added, and each group had 6 replicate wells. After 2 hours of pre-incubation, 100 μM hydrogen peroxide was added to the model group and the treatment group respectively. After 30 ...

Embodiment 2

[0032] Example 2 Neuroprotective effects of drugs on Alzheimer's disease model SAMP8 mice

[0033] 1. Experimental materials

[0034] 36 clean-grade 39-week-old male SAMP8 senile dementia mice, weighing 30g ± 2g; 12 SAMR1 anti-aging mice of the same age, all provided by the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine (animal qualification certificate number: W-J Jinshi Momentum M Zhunzi No. 006). They were routinely housed in the Animal Room of West China School of Pharmacy, Sichuan University.

[0035]Reagents and medicines: Compound 1 disclosed in the present invention has a purity >99%, and is prepared at the required concentration before use. The rest of the reagents were commercially available analytically pure.

[0036] 2. Methods and results

[0037] 2.1 Animal grouping and administration

[0038] All mice were adapted to the experimental environment for 7 days before administration, and were randomly divided into model gro...

Embodiment 3

[0053] Example 3 Neuroprotective effects of drugs on rats with vascular dementia

[0054] 1. Experimental materials

[0055] Male Wistar rats, weighing 280–300 g, were purchased from the Animal Experiment Center of Sichuan University. They were routinely housed in the Animal Room of West China School of Pharmacy, Sichuan University.

[0056] Reagents and medicines: Compound 1 disclosed in the present invention has a purity >99%, and is prepared at the required concentration before use. The rest of the reagents were commercially available analytically pure.

[0057] 2. Methods and results

[0058] 2.1 Animal modeling, grouping and administration

[0059] Rats were anesthetized by intraperitoneal injection of 3.5% chloral hydrate (350 mg / kg), the bilateral common carotid arteries were separated and ligated, and the bilateral common carotid arteries were not ligated in the sham-operated normal group. Seven days after the operation, the hidden platform screening experi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a salicylic acid compound and a medicinal composition of a pharmaceutically acceptable salt thereof. The compound can be added into a pharmaceutically permissible excipient to prepare various pharmaceutically acceptable medicinal preparations. Research proves that the compound disclosed by the invention has a protection effect on in-vitro cultured nerve cell damage induced by hydrogen peroxide, the learning and memory capabilities and the neuron-pathologic change of patients with senile dementia and vascular dementia can be dose-dependently improved, and the compound can be used for effectively treating and / or preventing the neurodegenerative related disease.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of a class of salicylic acid compounds and pharmaceutically acceptable salts thereof in the preparation of drugs for the treatment and / or prevention of neurodegenerative related diseases, including but not limited to vascular dementia, Alzheimer's Neurodegenerative diseases such as Haimer's disease (Alzheimer's disease), Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, neuropathic pain, glaucoma, etc. Background technique [0002] Vascular dementia (VD) is a mental and cognitive disorder caused by various types of cerebrovascular diseases (including ischemic cerebrovascular disease, hemorrhagic cerebrovascular disease, acute and chronic hypoxic cerebrovascular disease, etc.). It is a clinical syndrome of cognitive dysfunction, and its main clinical manifestations include: decline in cognitive ability, memory, and soc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C65/28C07C65/19A61K31/603A61P25/28A61P25/16A61P25/14A61P25/00A61P27/06
Inventor 杜俊蓉邓勇陈雏
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com